VolitionRx Limited (VNRX) Total Debt to Capital

VolitionRx Limited - graphic logo of issuer VNRX

VolitionRx Limited (VNRX) develops affordable blood analysis systems for the early detection of oncology. Serving as the primary assessment tool, this price chart demonstrates a metric at 0.00. The company is expanding its Nu.Q platform by implementing panels for veterinary use and screening. However, costly research, slow physician adoption of methodologies, and potential revisions to insurance reimbursements could undermine financial stability.

VolitionRx Ltd. (VNRX): Debt to Equity Ratio from 07/04/2022 to 10/30/2026

Metric breakdowns and analytics for VolitionRx (VNRX)

- share price and consensus valuation forecast:
Stock Price VolitionRx Ltd.|VNRX - Consensus Target
- market capitalization details:
Market Capitalization VolitionRx|VNRX - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share VolitionRx|VNRX - Accounting Capitalization|Market Capitalization to Book Value Ratio volition.com|VNRX - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital VolitionRx Limited|VNRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity VolitionRx Ltd.|VNRX - Aggregate Debt Obligations|Debt to Book Value VolitionRx|VNRX - Company Long-Term Loans and Borrowings|Company Short-Term Debts VolitionRx|Quick Liquidity volition.com
- net income and valuation ratios data:
VNRX - Company Profit
Fundamental company valuation:VolitionRx Limited
Finished products of VolitionRx Ltd.

This indicator is calculated as the ratio of total debt obligations to equity, determining the degree of financial leverage and the business's dependence on borrowed capital. By analyzing the current total liabilities-to-equity ratio of 0.00, an investor can see the stability of VolitionRx Limited (VNRX), whose cancer diagnostics development in the US and Belgium is shielded from geopolitical risks, minimizing the need for emergency lending.

Competitor analysis for VolitionRx Limited

CAI (Caris Life Sciences) - Total Debt to Capital|Total Debt to Equity Ratio Guardant Health Inc (GH)|Total Debt to Capital VCYT|Total Debt to Capital Celcuity Therapeutics (CELC)|Debt to Equity GRAIL, Inc. GRAL|MYGN: Debt to Equity Ratio|Castle Biosciences, Inc. - Total Debt to Capital|Burning Rock Biotech Limited (BNR) - Total Debt to Equity Ratio|BDSX: Total Debt to Capital|Debt to Capital Precipio Inc (PRPO)|Debt to Equity Check-Cap Ltd|MYNZ: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio OCX (OncoCyte)